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Introduction: Transducin (β)-like 1 X-linked receptor 1(TBLR1) is an F-box-like and WD repeat-containing protein
which functions as a switch in transcriptional activation, However, the clinical significance and biological role of
TBLR1 in breast cancer remains largely unknown.
Methods: Western blotting, immunocytochemistry and real-time PCR were used to evaluate TBLR1 expression in
normal breast epithelial cells and breast cancer cell lines, clinical tissue samples and adjacent nontumor tissues,
and in 214 paraffin-embedded specimens. Statistical analyses were used to test for the prognostic and
diagnostic associations. The biological role of TBLR1 -induced proliferation and tumorigenicity in breast cancer
cells was explored in vitro and in vivo. The effect of TBLR1 on the expression of cyclin D1 and β-catenin
signaling was examined by Western blotting, luciferase reporter assay and by several immunoprecipitation
techniques.
Results: TBLR1 was significantly upregulated in breast cancer cells and tissues compared to normal control samples.
Immunohistochemical analysis revealed high expression of TBLR1 in 113 of 214 (52.8%) paraffin-embedded archival
breast cancer. The overall expression level of TBLR1 was significantly correlated with clinical stage (P <0.001), the
tumor classification (P <0.001), node classification (P =0.024), and metastasis classification (P = 0.004), histological
grade (P = 0.044), as well as with the expression level of c-erbB2 (P = 0.036) and Ki-67 (P <0.001). Patients with higher
TBLR1 expression had shorter overall survival time, whereas patients with lower TBLR1 expression had better
survival. Multivariate analysis suggested that TBLR1 expression might be an independent prognostic indicator
for the survival of breast cancer patients. TBLR1 overexpression promoted, whereas TBLR1 silencing inhibited,
proliferation and tumorigenicity in breast cancer cells both in vitro and in vivo. We found that TBLR1 expression
was implicated in the upregulation of cyclin D1, phosphorylation of cell-cycle control protein Rb (pRb) and activation
of β-catenin signaling in breast cancer.
Conclusions: TBLR1 plays a key role in the development and progression of breast cancer cells via cyclin
D1-transactivation and activation of the β-catenin signaling pathway. TBLR1 may be a novel prognostic marker
and a potential therapeutic target in the treatment human breast cancer.* Correspondence: yuanzhy@sysucc.org.cn
1Department of Experimental Research, State Key Laboratory of Oncology in
Southern China, Cancer Center, Sun Yat-sen University, Guangzhou,
Guangdong, China
4Medicine Oncology, Cancer Center, Sun Yat-sen
University, Guangzhou, Guangdong, China
Full list of author information is available at the end of the article
© 2014 Li et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Li et al. Breast Cancer Research 2014, 16:465 Page 2 of 16
http://breast-cancer-research.com/content/16/5/465Introduction
Breast cancer is the most common cancer and a leading
cause of cancer death among women, with approxi-
mately 232,340 new cases and 39,620 deaths predicted
in the US in 2013 [1]. Although previous research has
shown that the etiology of breast cancer includes herit-
able factors and genetic mutations [2-4], the molecular
mechanism is poorly understood [5]. Patients with dif-
ferent molecular and clinical characteristics present dif-
ferent biological and therapeutic responses, however
conventional clinical characteristics, such as tumor size,
lymph node involvement, distant metastasis status and
tumor differentiation, have limitations due to the com-
plexity of tumor progression [6-9]. Therefore, identifying
gene and protein markers will facilitate the development
of novel diagnostic and prognostic indicators for improved
therapies and individualized treatments in patients with
breast cancer.
Transducin (β)-like 1 X-linked receptor (TBLR1) is an
F-box/WD-40-containing factor which was initially iden-
tified as a component of an SMRT/N-CoR corepressor
complex. It is a member of the TBL1 family, which is
encoded by a distinct gene located on Chromosome 3 and
is highly homologous to the TBL1 protein encoded by the
TBL1X gene. TBLR1 is thought to control the switch
from gene repression to gene activation of nuclear re-
ceptors and other molecules required for transcriptional
activation, including estrogen receptor (ER), androgen
receptor (AR), thyroid hormone receptor β (TRβ), peroxi-
some proliferator-activated receptor γ (PPARγ), nuclear
factor kappa-light-chain-enhancer of activated B cells
(NF-κB), Notch and β-catenin [10-16]. TBLR1 also func-
tions as an E3-ligase by recruiting UbcH5 ubiquitin conjugat-
ing enzymes/19S proteasome, leading to the replacement
of corepressors with coactivators in a ligand-dependent
manner [10,12,16]. Although previous studies have shown
that TBLR1 is highly expressed in lung squamous cell car-
cinoma [17], the clinical significance and biological func-
tion of TBLR1 in the progression of breast cancer remain
to be established.
In this study, we found that TBLR1 was significantly
upregulated in breast cancer cells and tissues both in vitro
and in vivo, and that its expression was closely correlated
with clinicopathologic features in breast cancer. Further-
more, we have demonstrated that TBLR1 may promote
proliferation and tumorigenicity in breast cancer through




Primary normal breast epithelial cells (NBECs) were col-
lected from a woman's mammoplasty material at the
Department of Plastic Surgery, the First Affiliated Hospitalof Sun Yat-sen University (PR China), according to the
rules and regulations relating ethical issues on research
use of human subjects in China, and established ac-
cording to the previous report [18], Breast cancer cell
lines, including Bcap-37 was obtained from the Cell Bank
of the Chinese Academy of Sciences (Shanghai, China),
MCF-7, BT-549, SKBR3, MDA-MB-231,ZR-75-1, MDA-
MB-468, MDA-MB-415, MDA-MB-361, ZR-75-30,T47D
and MDA-MB-435 were purchased from ATCC and cul-
tured in Dulbecco’s modified Eagle’s medium (Gibco,
Grand Island, NY, USA) supplemented with 10% fetal bo-
vine serum (HyClone, Logan, UT, USA) and 100 μg/μL
streptomycin, and 100 μg/μL penicillin in a humidified in-
cubator containing 5% CO2 at 37°C.
Patient information and tissue specimens
This study was conducted on a total of 214 paraffin-
embedded breast cancer samples, which were histopatho-
logically and clinically diagnosed at the Sun Yat-sen
University Cancer Center from 1999 to 2001. Clinical
and clinicopathological classification and stage were deter-
mined according to the American Joint Committee on
Cancer (AJCC) criteria. The histological grade was deter-
mined according to the Elston-Ellis modification of the
Scarff-Bloom-Richardson (SBR) system. Tissues were ob-
tained from patients who were subsequently diagnosed
with breast cancer: 8 freshly collected paired breast tissues
and 10 freshly prepared human breast cancer tissues
were frozen and stored in liquid nitrogen until further
use. For the use of these clinical materials for research pur-
poses, prior consent of the patients and approval from the
Institutional Research Ethics Committee of Sun Yat-sen
University were obtained. Clinical information related to
the samples is summarized in Table 1.
RNA extraction, reverse transcription, and real-time PCR
Total RNA from cultured cells and fresh tissues were ex-
tracted using the Trizol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instruction.
The extracted RNA was pretreated with RNase-free DNase,
and about 2ug RNA from each sample was used for cDNA
synthesis with iScriptcDNA Synthesis Kit (Bio-Rad
Laboratories, Hercules, CA, USA). cDNAs were ampli-
fied and quantified in ABI Prism 7500 Sequence Detection
System (Applied Biosystems, Texas, US) by using dye
SYBR Green I (Molecular Probes, Basel, Switzerland). Ex-
pression data were normalized to the geometric mean of
housekeeping gene GAPDH to control the variability in
expression levels and calculated as:
2 Ct of TBLR1ð Þ− Ct of GAPDHð Þ½ 
where Ct represents the threshold cycle for each transcript.
Table 1 Clinicopathological characteristics of patient
samples and expression of transducin (β)-like 1 X-linked
receptor 1 in breast cancer






























Moderately differentiated 152 (71.0)
Poorly differentiated 54 (25.3)
Expression of transducin (β)-like
1 X-linked receptor 1
Low expression 103 (48.1)
High expression 111 (51.9)
Detectable 214 (100.0)
Undetectable 0 (0.0)





Table 1 Clinicopathological characteristics of patient
samples and expression of transducin (β)-like 1 X-linked
receptor 1 in breast cancer (Continued)
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A TBLR1 expression construct was generated by subclon-
ing PCR-amplified full-length human TBLR1 cDNA into
the pSin-EF2 vector. For depletion of TBLR1 to silence
endogenous TBLR1, two short hairpin RNA (shRNA) oli-
gonucleotides were cloned into the pSuper-retro-puro
vector to generate pSuper-retro-TBLR1-RNAi(s), respect-
ively. The human Cyclin D1 promoter luciferase plasmid
was purchased from Addgene (Cambridge, MA, USA).
Transfection of siRNAs or plasmids was performed using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) ac-
cording to the manufacturer’s instructions. Stable cell lines
expressing TBLR1 and TBLR1-shRNA were generated via
retroviral infection using HEK293T cells as previously
described and selected with 0.5 μg/mL puromycin for
10 days.
Western blotting
Western blot analysis was carried out according to stand-
ard methods as described previously [18], using anti-
TBLR1 (Sigma, Saint Louis, MI, USA), anti-cyclin D1,
anti-pRb, anti-Rb (Cell Signaling, Danvers, MA, USA). To
control sample loading, the blotting membranes were
stripped and re-probed with an anti-α-tubulin anti-
body (Sigma).
Immunohistochemistry (IHC)
IHC staining was carried out using Histostain-Plus Kits
(Invitrogen) following the manufacturer's protocols;
IHC-stained tumor sections were examined and scored
independently by two observers for positively stained
tumor cells and the intensity of IHC signals [19-21]. The
proportion of tumor cells was scored as follows: 0 (no
positive tumor cells), 1 (1% to 25% positive tumor cells),
2 (26% to 0% positive tumor cells), 3 (51% to 75%
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cells). The intensity of staining was graded according to
the following criteria: 0 (no staining); 1 (weak staining =
light yellow), 2 (moderate staining = yellow brown), and
3 (strong staining = brown). The staining index was cal-
culated as staining intensity score × proportion of posi-
tive tumor cells (range from 0 to 12). Optimal cutoff
values were chosen on the basis of a measure of hetero-
geneity with the log-rank test statistical analysis with re-
spect to overall survival.MTT assay
Cells were seeded in 96-well plates at an initial density
of 2 × 103/well. At each time point, cells were stained with
100 μL sterile 3-(4,5-Dimethyl-2-thiazolyl)- 2,5-diphenyl-
2H-tetrazolium bromide (MTT) dye (0.5 mg/mL, Sigma)
for 4 hours at 37°C, followed by removal of the culture
medium and addition of 100 μL of dimethyl sulphoxide
(Sigma). The absorbance was measured at 570 nm, with
655 nm as the reference wavelength. All experiments were
carried out in triplicates.Anchorage-independent growth ability assay
Five hundred cells were trypsinized and suspended in
2 mL of complete medium plus 0.3% agar (Sigma). The
agar-cell mixture was plated on top of a bottom layer
with 1% agar completed medium mixture. At 10 days,
viable colonies that were larger than 0.1 mm were
counted. The experiment was carried out for each cell
line in triplicate.Colony formation assays
Cells were plated in 6-well plates (1 × 103 cells per plate)
and cultured for 10 days. The colonies were stained with
1% crystal violet for 30 seconds after fixation with 4%
formaldehyde for 5 minutes.Flow cytometry
Cells were harvested, washed with cold 1 × PBS, and
processed for cell cycle analysis using flow cytometry.
Briefly, the cells were fixed in 75% ethanol and stored at
4°C overnight for later analysis. The fixed cells were cen-
trifuged at 1,000 rpm for 5 minutes and washed with
cold PBS twice. RNase A (20 μg/ml final concentration)
and propidium iodide staining solution (50 μg/mL final
concentration) were added to the cells and incubated for
30 minutes at 37°C in the dark. Twenty thousand cells
were analyzed using a CytomicsTM FC 500 instrument
(Beckman Coulter, Brea, California, USA) equipped with
CXP software. Modfit LT 3.1 trial cell cycle analysis soft-
ware was used to determine the percentage of cells in
the different phases of the cell cycle.Bromodeoxyuridine labeling and immunofluorescence
Cells (5 × 104) were plated on coverslips (Fisher 12-545-
80, Fisher Scientific, Pittsburgh, PA, USA). After 24 hours,
cells were incubated with 5-bromodeoxyuridine (BrdU)
for 1 hour and stained with anti-BrdU antibody (Upstate,
Billerica, MA, USA) according to the manufacturer’s
instruction. Gray-level images were acquired under a
laser scanning microscope (Axioskop 2 plus; Carl Zeiss
Co Ltd, Oberkochen, Germany).
Xenografted tumor model
Female BALB/c-nu mice (4–5 weeks of age, 14 to 16 g)
were purchased from the Center of Experimental Animal
of Guangzhou University of Chinese Medicine, and were
housed in barrier facilities on a 12-hour light/dark cycle.
All experimental procedures were approved by the
Institutional Animal Care and Use Committee of Sun
Yat-sen University. The BALB/c nude mice were randomly
divided into twp groups (n =5/group). A 0.72 mg E2
60-day release pellet (Innovative Research of America)
was implanted subcutaneously on the dorsal side of each
mouse 1 day before tumor cell implantation to support
the growth of the estrogen-dependent MCF-7 cell-derived
tumors. For tumor cell implantation, MCF-7-TBLR1
or MCF-7-TBLR1-RNAi or their respective control cells
(1 × 107) in 100 μL of the mixture were subcutaneously
injected into the mice. Tumors were examined once every
other day: length, width, and thickness measurements
were obtained with calipers and tumor volumes were cal-
culated. On day 42, animals were euthanized, and tumors
were excised and weighed.
Luciferase reporter assay
Cells (3 × 103) were seeded in triplicate in 48-well plates
and allowed to settle for 24 hours, then 100 ng luciferase re-
porter plasmids or the control luciferase plasmid plus 1 ng
pRL-TK renilla plasmid (Promega, Madison, Wisconsin)
were transfected into breast cancer cells using Lipofecta-
mine 2000 reagent (Invitrogen). Forty-eight hours after
transfection, Dual-Luciferase Reporter Assay (Promega)
was performed according to the manufacturer’s instruc-
tions. Three independent experiments were performed
and the data are presented as the mean ± SD.
Chromatin immunoprecipitation (ChIP) assays
Cells (2 × 106) were plated per 100-mm diameter dish
and treated with formaldehyde to crosslink chromatin-
associated proteins to DNA. The cells were trypsinized
and resuspended in lysis buffer, and nuclei were isolated
and sonicated to shear the DNA to 500 bp to 1 kb frag-
ments (verified by agarose gel electrophoresis). Equal ali-
quots of chromatin supernatants were separated and
incubated with different antibodies as indicated or anti-
IgG antibody as a negative control overnight at 4°C with
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D1 and MYC were amplified by PCR. All ChIP assays
were performed three times and representative results
are presented.
Statistical analysis
All statistical analyses were carried out using the SPSS
version 16.0 statistical software packages. The correlation
between TBLR1 expression and the clinicopathological
characteristics was analyzed by the chi-square test. Sur-
vival curves were plotted by the Kaplan-Meier method
and compared with the log-rank test. The significance of
various variables for survival was analyzed by the Cox pro-
portional hazards model in the multivariate analysis. The
differences between experimental conditions were com-
pared using Student’s t-test. P <0.05 was considered statis-
tically significant.
Results
TBLR1 is upregulated in human breast cancer cells
Expression of TBLR1 was examined in breast cancer
cells and tissues. The results of western blot and real-Figure 1 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) expression
shows the TBLR1 protein levels in normal breast epithelial cells (NBEC) and
(B and C) Western blotting and immunohistochemistry staining, respective
breast tumor tissue samples (T) and adjacent non-tumor tissues (ANT) fromtime PCR analyses showed that expression of TBLR1
was significantly upregulated at both the protein and
mRNA levels in 12 tested breast cancer cell lines rela-
tive to NBECs (Figure 1A; Additional file 1: Figure S1A).
Similarly, western blotting and IHC showed that TBLR1
protein was upregulated in breast cancer tissue sam-
ples compared to their matched adjacent non-tumor
tissues from the same patient (Figure 1B and C); and
real-time PCR revealed that TBLR1 mRNA was also sig-
nificantly upregulated in breast cancer tissues (Additional
file 1: Figure S1B).
TBLR1 expression is associated with clinical features in
breast cancer
The clinical significance of the upregulation of TBLR1 in
breast cancer was examined by IHC and correlated with
the clinical characteristics of 214 paraffin-embedded
breast cancer tissue specimens, including 21 (9.8%) cases
with stage I, 107 (50.0%) cases with stage II, 66 (30.8%)
cases with stage III and 20 (9.3%) cases with stage IV tu-
mors. We found that TBLR1 was markedly upregulated
in breast cancer tissues, but was only detectable at lowis elevated in breast cancer cells and tissues. (A) Western blotting
in 12 breast cancer cell lines; α-Tubulin was used as a loading control.
ly, show the expression levels of TBLR1 protein in each of the primary
the same patient.
Figure 2 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) is upregulated in archived breast cancer tissues. (A) Representative
immunohistochemistry fluorescent micrographs showing TBLR1 expression levels in normal and tumor breast tissue samples from cases with
different clinical stages (I to IV); magnification, 200× and 400×. (B) Quantification analyses of mean TBLR1 expression levels in normal breast
tissues (n = 3) and breast tumor tissues from cases with different clinical stages (n =16/stage); MOD, mean optical density. (C) Kaplan-Meier
survival curves comparing cumulative overall survival rates in patients with low and high TBLR1 expression levels. (D) Survival curves for breast
cancer patients with clinical stage I to II (left) and clinical stage III to IV (right) disease.
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analysis indicated that the average mean optical dens-
ity (MOD) of TBLR1 staining in clinical stage I to IV
primary tumors were statistically significantly higher than
the value in normal breast tissues (P <0.001; Figure 2B).
As shown in Table 2, detailed analyses revealed that
expression of TBLR1was significantly associated with
clinical stage (P <0.001), tumor (T) classification (P <0.001),
node (N) classification (P = 0.024), metastasis (M) classi-
fication (P = 0.004), pathological differentiation (P =
0.044), c-erbB-2 expression (P = 0.036) and Ki-67 ex-
pression (P <0.001). However, it was not associated with
patient age, estrogen receptor (ER) or progesterone re-
ceptor (PR) status. The Spearman correlation coeffi-
cients between TBLR1 expression and clinical stage, T
classification, N classification, M classification, patho-
logical differentiation, and Ki-67 expression were 0.215
(P = 0.002), 0.522 (P <0.001), 0.139 (P = 0.042), 0.197
(P = 0.004), 0.136 (P = 0.047), and 0.630 (P <0.001),
respectively (Table 3). Taken together, these results indi-
cated that expression of TBLR1 was correlated with many
of the key clinical features of breast cancer.Increased expression of TBLR1 is correlated with the
prognosis of breast cancer patients
Patient survival analysis was conducted and revealed that
TBLR1 protein expression in primary breast cancer was sig-
nificantly inversely correlated with the survival time of pa-
tients (r = −0.512, P <0.001; Table 3). Kaplan-Meier survival
curves showed that patients with high levels of TBLR1 had
significantly shorter overall survival (OS) rates than those
with low levels of TBLR1 (P <0.001; Figure 2C). The cumu-
lative 5-year survival rates in patients with low levels of
TBLR1 expression were 86.4% (95% confidence interval
0.791 to 0.937), compared to 51.9% (95% confidence inter-
val 0.421 to 0.617) in those with high levels of TBLR1 ex-
pression. Furthermore, univariate and multivariate analyses
confirmed that clinical stage, pathological differentiation
and Ki-67, as well as TBLR1 expression, were identified as
independent prognostic factors, as shown in Table 4. Taken
together, these results indicated that TBLR1 might be a
novel and potentially valuable independent prognostic bio-
marker in patients with breast cancer. The prognostic value
of TBLR1 expression in patients with breast cancer was also
evaluated by analyzing survival times in different patient
Table 2 Clinicopathological characteristics of patient samples and expression of TBLR1 in breast cancer and correlation
between TBLR1 expression and clinicopathological characteristics of breast cancer patients
Characteristics Total Transducin (β)-like 1 X-linked receptor 1 (TBLR1) Chi-square
test P-valueLow expression (%) High expression (%)
Age, years <47 101 53 (50.0) 48 (44.4) 0.416
≥47 113 53 (50.0) 60 (55.6)
Clinical stage I 21 17 (16.8) 4 (3.5) <0.001
I 107 50 (49.5) 57 (50.4)
III 66 31 (30.7) 35 (31.0)
IV 20 3 (3.0) 17 (15.0)
Tumor classification T1 69 57 (56.4) 12 (10.6) <0.001
T2 113 41 (40.6) 72 (63.7)
T3 24 3 (3.0) 21 (18.6)
T4 8 0 (0.0) 8 (7.1)
Node classification N0 67 40 (39.6) 27 (23.9) 0.024
N1 80 32 (31.7) 48 (42.5)
N2 63 29 (28.7) 34 (30.1)
N3 4 0 (0.0) 4 (3.5)
Metastasis classification Yes 22 4 (4.0) 18 (16.0) 0.004
No 192 97 (96.0) 95 (84.1)
Pathological differentiation Well-differentiated 8 3 (3.0) 5 (4.4) 0.044
Moderately differentiated 152 80 (79.2) 72 (63.7)
Poorly differentiated 54 18 (17.8) 36 (31.9)
Expression of estrogen receptor 0 91 47 (46.5) 44 (38.9) 0.545
1 98 41 (40.6) 57 (50.4)
2 14 7 (6.9) 7 (6.2)
3 11 6 (5.9) 5 (4.4)
Expression of progesterone receptor 0 76 33 (32.7) 43 (38.1) 0.139
1 99 53 (52.5) 46 (40.7)
2 27 12 (11.9) 15 (13.3)
3 11 2 (2.0) 9 (8.0)
4 1 1 (1.0) 0 (0.0)
Expression of C-erbB-2 0 36 16 (26.2) 20 (37.0) 0.036
1 33 25 (41.0) 8 (14.8)
2 29 12 (20.0) 17 (31.5)
3 14 6 (9.8) 8 (14.8)
4 3 2 (3.3) 1 (1.9)
Expression of Ki-67 1 111 86 (85.1) 25 (22.1) <0.001
2 103 15 (14.9) 88 (77.9)
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patients with high TBLR1 expression had significantly
lower OS rates compared with those with a low level of
TBLR1 expression in the early clinical subgroup (stages I
to II, n = 128; log-rank, P <0.001; Figure 2D, left panel)
and the advanced disease subgroup (stages III to IV, n =
86; log-rank, P <0.001; Figure 2D, right panel). All in all,our data suggest that TBLR1 might be a novel and poten-
tially useful independent biomarker for the prognosis of
patients with breast cancer.
TBLR1 promotes proliferation in breast cancer cells
The biological role of TBLR1 in breast cancer was further
explored by employing IHC to examine the relationship
Table 3 Spearman correlation between transducin (β)-like
1 X-linked receptor 1 (TBLR1) and clinical pathologic
factors
Variables TBLR1 expression level
Spearman correlation P-value
Clinical staging 0.215 0.002
Tumor classification 0.522 <0.001
Node classification 0.139 0.042
Metastasis classification 0.197 0.004
Pathological differentiation 0.136 0.047
Expression of Ki67 0.630 <0.001
Survival time −0.512 <0.001
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(Tables 2, 3 and Additional file 2: Figure S2). The results
supported our earlier findings by showing that TBLR1 was
positively correlated with Ki-67 expression. This sug-
gests that upregulation of TBLR1 promoted proliferation
in breast cancer cells.
To confirm the biological role of TBLR1 in breast cancer,
stable cell lines overexpressing TBLR1 were established
by subcloning full-length human TBLR1 cDNA into the
pSin-EF2 vector (Figure 3A). MTT assays showed an ap-
proximately two-fold increase in the number of TBLR1-
overexpressing cells relative to vector control cells after



















Transducin (β)-like 1 X-linked receptor 1 (TBLR1) protein expression level in breast can
coefficient was −0.512 indicating that higher levels of TBLR1 expression correlate with
high expression, 51.9% (42.1% to 61.7%).expression of TBLR1 increased the proliferative capacity
of breast cancer cells. A similar result was shown by the
colony formation assays (Figure 3C). Conversely, knock-
down of endogenous TBLR1 expression using two TBLR1-
specific shRNAs (Figure 4A) showed that TBLR1-silencing
significantly inhibited cell proliferation, leading to more
than a two-fold decrease in cell number compared to
vector controls after 4 days of culture (P <0.05; Figure 4B).
These results were consistent with the colony formation
assays (Figure 4C). A BrdU-incorporation assay was per-
formed in SKBR3 and MCF-7 cell lines to assess the
mechanism underlying the promotion of cellular prolifera-
tion by TBLR1. The results showed that the percentage of
BrdU positive cells was significantly increased in TBLR1-
overexpressing cells and was significantly decreased in
TBLR1-knockdown cells (Figures 3D and 4D). Similarly,
flow cytometric analysis showed that overexpression of
TBLR1 markedly decreased the percentage of cells in G0/
G1 phase and increased the percentage of cells in S phase;
whereas silencing TBLR1 induced the converse effects
(Figures 3E and 4E). In line with our earlier observations,
these results confirmed that TBLR1 is involved in promot-
ing proliferation in breast cancer cells.
TBLR1 promotes the tumorigenicity of breast cancer cells
in vitro and in vivo
Because TBLR1 expression was correlated with the clinical




P-value Relative risk 95% confidence
interval
1.642 (0.301) 0.012 2.590 1.237, 5.422
1.518 (0.283) 0.034 2.126 1.058, 4.271
0.804 (0.158) 0.007 1.593 1.135, 2.237
0.873 (0.258) 0.026 1.809 1.074, 3.050
cer significantly correlated with patient survival time (P <0.001). The correlation
shorter survival time. For 5-year survival: low expression, 86.4% (79.1% to 93.7%);
Figure 3 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) overexpression promotes cell proliferation and G1-S phase transition
in breast cancer cells. (A) Western blotting shows the levels of TBLR1 protein in TBLR1-overexpressing breast cancer cell lines;
glyceraldehyde-3-phosphate dehydrogenase was used as a loading control. (B and C) MTT and colony formation assays, respectively, show
that growth rates and colony sizes are increased in TBLR1-overexpressing breast cancer cells. (D) Representative micrographs (left panel) and
quantification (right panel) of 5-bromodeoxy uridine (BrdU)-incorporated breast cancer cells. DAPI, 4',6-diamidino-2-phenylindole.
(E) Flow cytometric analyses showing the percentages of cells of TBLR1-overexpressing cells and vector control cells at different phases
of the cell-cycle. The data are representative of three independent experiments. All values are given as the mean ± SD of three independent
experiments; *P <0.05.
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tumorigenic activity of breast cancer cells. Anchorage-
independent growth assays demonstrated that the growth
capacity of SKBR3 and MCF-7 breast cancer cell lines was
significantly enhanced by TBLR1-overexpression, as shown
by the increased number and size of colonies (Figure 5A).
Conversely, the growth capacity of both SKBR3 and
MCF-7 cells could be compromised by downregulation of
TBLR1, as revealed by the decreased number and size
of colonies (Figure 5B). Moreover, to determine whether
TBLR1 promoted tumorigenicity in breast cancer cellsin vivo, we established a xenograft model by inoculat-
ing nude mice (n =5/group) with MCF-7/TBLR1 or MCF-7/
TBLR1-RNAi cells or their respective control vectors
(MCF-7/vector or MCF-7/RNAi-vector). The tumors
formed by the TBLR1-overexpressing cells grew signifi-
cantly faster, were larger and had greater masses than
those formed by their vector controls at each time point;
whereas, tumors formed by TBLR1-knockdown cells
grew significantly slower, were smaller and had lower
masses than those formed by shRNA vector control cells
(P <0.001; Figure 5C,D and E). Of note, IHC revealed that
Figure 4 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) silencing inhibits cell proliferation and G1-S phase transition in breast
cancer cells. (A) Western blotting shows the levels of TBLR1 protein in TBLR1-silenced breast cancer cells; glyceraldehyde-3-phosphate
dehydrogenase was used as a loading control. (B and C) MTT and colony formation assays, respectively, show that growth rates and
colony sizes are decreased in TBLR1-silenced cells. DAPI, 4',6-diamidino-2-phenylindole. (D) Representative micrographs (left panel) and
quantification (right panel) of 5-bromodeoxy uridine (BrdU)-incorporated breast cancer cells. (E) Flow cytometric analyses showing the
percentages of TBLR1-shRNA transfected cells and vector controls at different phases of the cell cycle. The data are representative of
three independent experiments. All values are given as the mean ± SD of three independent experiments; *P <0.05.
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higher levels of cyclin D1 and Ki-67 staining, and a
greater proliferative index than tumors formed by TBLR1-
knockdown cells (Figure 5F). Therefore, the in vivo results
were consistent with our in vitro observations, confirming
that TBLR1 plays an important role in enhancing the
tumorigenicity of breast cancer cells.
TBLR1 promotes cell proliferation via activation of the
β-catenin signaling pathway
Consistent with the aforementioned results, the phosphor-
ylated Rb was also increased in the TBLR1 overexpressing-cells and decreased in the TBLR1 silencing cells, further
demonstrating that TBLR1 plays an important role in the
proliferation of HCC cells (Figure 6A). Interestingly, we
found that both transcriptional and translational levels of
CDK regulator cyclin D1 were upregulated by TBLR1 over-
expression, but supressed by TBLR1 silencing, as com-
pared with that in control cells (Figure 6A and B).
Importantly, the stimulatory effect of TBLR1 on the
cyclin D1 expression was abolished by the inhibition of
Wnt/β-catenin signaling via TCF4 dominant-negative
mutant (TCF4-dn) transfection, suggesting that TBLR1
might activate Wnt/β-catenin signaling. As expected, the
Figure 5 (See legend on next page.)
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Figure 5 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) contributes to breast cancer progression in vitro and in vivo. (A and B)
Anchorage-independent growth assays in TBLR1-overexpressing cells and TBLR1-silenced cells, respectively. Quantification of the soft agar colony
formations was based on colonies >0.1 mm in diameter after 10 days of culture. (C-E) Xenograft model in nude mice inoculated with either
TBLR1-overexpressing or TBLR1-knockdown breast cancer cells, or their respective vector control cells (n =5/group) 42 days after inoculation.
(C) Growth curves showing changes in tumor volume; (D) images showing changes in tumor size; (E) mean tumor weights. (F) H&E and
immunohistochemical staining showed that overexpression of TBLR1 induced, whereas suppression of TBLR1 inhibited, the tumorigenicity
of breast cancer cells in vivo, as indicated by the percentage of Ki-67 positive cells. All data are presented as mean ± SD of three independent
experiments; *P <0.05.
Figure 6 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) activates β-catenin signaling. (A) Western blotting shows the protein levels of
cyclin D1, pRb and total Rb in breast cancer cell lines; α-tubulin was used as a loading control. (B) Real-time PCR analysis shows the relative
expression of cyclin D1 mRNA in breast cancer cell lines. Expression levels were normalized against glyceraldehyde-3-phosphate dehydrogenase.
(C) Indicated cells transfected with TOPflash or FOPflash and Renilla pRL-TK plasmids were subjected to dual-luciferase assays 48 hours after
transfection. Reporter activity detected was normalized by Renilla luciferase activity. (D) Real-time PCR analysis indicates an apparent overlap
between β-catenin-dependent genes and TBLR1-regulated genes. The pseudocolor represents the intensity scale of TBLR1 versus vector control,
or TBLR1 siRNA versus negative control, generated by a log2 transformation. (E) Chromatin immunoprecipitation assays showing the levels of
endogenous β-catenin protein bound to cyclin D1 and MYC promoters in TBLR1 breast cancer cells and vector control cells; Error bars represents
the mean ± SD of three independent experiments; *P <0.05.
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Figure 7 Inhibition of Wnt/β-catenin signaling blocked the functional role of transducin (β)-like 1 X-linked receptor 1 (TBLR1). (A) Western
blotting shows the protein levels of TBLR1, TCF4-dn, pRb and total Rb in breast cancer cell lines; α-tubulin was used as a loading control.
(B) Indicated cells transfected with TOPflash or FOPflash and Renilla pRL-TK plasmids were subjected to dual-luciferase assays 48 hours
after transfection. Reporter activity detected was normalized by Renilla luciferase activity. (C) PCR analysis shows the expression of cyclin D1,
MYC and AXIN2 mRNA in breast cancer cell lines. Expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase. (D) Representative
micrographs (left) and quantification (right) of crystal violet-stained cell colonies. (E) Anchorage-independent growth assays in indicated cells. (F) Flow
cytometry analysis examined the portions of cell cycle in SKBR3 cells.
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eight classically recognized Wnt/β-catenin target genes
were significantly increased in the TBLR1 overexpressing
breast cancer cells, but decreased in the TBLR1 silencing
cells (Figure 6C and D, Additional file 3: Figure S3). More-
over, the ChIP assay and Cyclin D1 promoter activity assay
revealed that TBLR1 might upregulate cyclin D1 and MYC
expression via direct binding to their promoters (Figure 6E
and Additional file 4: Figure S4).
Wnt/β-catenin signaling activation is vital to
TBLR1-induced cell proliferation
We further examined whether inhibiting wnt/β-catenin
signaling has a similar effect to knocking down TBLR1
expression. As shown in Figure 7A-C, knocking down of
TBLR1 or blocking wnt/β-catenin signaling by ectopically
expressing TCF4-dn, drastically reduced Rb phosphoryl-
ation, TOP/FOP activity and transcription of Cyclin D1,
MYC and AXIN2 in TBLR1-overexpressing cells. More-
over, both knocking down of TBLR1 and inhibition of
wnt/β-catenin signaling, abrogated the stimulatory ef-
fect of TBLR1 overexpression on breast cancer cell
growth and proliferation (Additional file 5: Figure S5
and Figure 7D-F). Thus, our results indicated that func-
tional wnt/β-catenin signaling activation is vital to TBLR1-
induced proliferation of breast cancer cells.
TBLR1 expression is positively correlated with cyclin D1
and β-catenin in human breast cancer tissues
To confirm whether the results obtained in breast can-
cer cell lines could also be observed in human primary
breast tumors, we examined the expression of TBLR1,
cyclin D1 and β-catenin in 10 freshly prepared breast
cancer tissues. Western blot and correlation analyses
showed that expression of TBLR1 was positively cor-
related with expression of cyclin D1 (r = 0.716; P = 0.002)
and nuclear β-catenin (r = 0.752; P <0.001) (Figure 8A
and B). These results further demonstrated that TBLR1Figure 8 Transducin (β)-like 1 X-linked receptor 1 (TBLR1) expression
expression in breast cancer tissues. (A and B) Western blotting (left) an
in 10 freshly prepared human breast cancer tissues; α-Tubulin and P84 wermediated proliferation in breast cancer cells via acti-
vation of the β-catenin signaling pathway.
Discussion
The pivotal finding of this study is that the elevated ex-
pression of TBLR1 correlated with a poor prognosis and
reduced survival of breast cancer patients, suggesting
that TBLR1 is a potential independent prognostic factor
for breast cancer. We found that TBLR1 is upregulated in
breast cancer cells at both the mRNA and protein levels
compared with normal breast epithelial cells. Overexpres-
sion of TBLR1 promotes the proliferation and tumorigen-
icity of breast cancer cells in vitro and in vivo. Moreover,
we showed that overexpression TBLR1 activated wnt/
β-catenin signaling pathway. These findings provide strong
evidence that upregulation of TBLR1 plays an important
role in promoting progression of breast cancer.
Tumorigenesis is a complex multi-step process char-
acterized by uncontrolled cell growth and tumor for-
mation. Reports have shown that tumorigenesis is
associated with the progressive accumulation of genetic
and epigenetic alterations in genes and proteins that
regulate cell proliferation, cell death and genomic in-
stability [22,23]. Therefore, identifying molecules that
promote tumorigenesis is central to the development
of novel diagnostic and prognostic markers, and po-
tential therapeutic targets in cancer. In this study, we
found that upregulation of TBLR1 dramatically pro-
moted cell proliferation and tumorigenicity in breast
cancer cells, both in vitro and in vivo. Furthermore,
expression of TBLR1 was significantly correlated with
clinicopathological characteristics and patient survival in
breast cancer. Importantly, knocking down of TBLR1
markedly reduced breast cancer cell proliferation and
tumorigenicity. Moreover, TBLR1 upregulation was also
observed in lung squamous cell carcinoma [17], suggeting
that TBLR1 upregulation might be a common event in
the progression of different cancers. Thus, our findingsis positively correlated with cyclin D1 and nuclear β-catenin
d correlation analyses (right) of TBLR1, Cyclin D1 and nuclear β-catenin
e used as the loading controls.
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velopment and progression of breast cancer, and sug-
gested TBLR1 might be a novel prognostic marker and
therapeutic target.
Of note, we found that TBLR1 expression was positively
correlated with the expression of C-erbB-2, which has been
found to be frequently amplified or overexpressed, to play
an important role in the development and progression of
certain aggressive types of breast cancer [24,25]. Function-
ing as a transcription co-factor, TBLR1 has been reported
to transcriptionally upregulate MYC and AXIN2 ex-
pression via binding to the β-catenin/TCF4 transcription
complex [13]. Thus, it would be of great interest and
importance to investigate whether TBLR1 upregulates
C-erbB-2 expression via β-catenin/TCF4 transcription
complex or others, and whether knocking down of TBLR1
could reduce the tumorigencity of C-erbB-2-overexpressing
breast tumors.
It has been reported that cyclin D1 plays an important
role in tumor development through regulation of the
cell cycle [26-29]. Our results showed that expression
of TBLR1 in human breast cancer cells was positively
correlated with expression of cyclin D1 and nuclear
β-catenin, and activation of genes downstream of β-
catenin. This indicates that TBLR1 may induce prolifer-
ation and tumorigenesis in breast cancer via activation of
the β-catenin signaling pathway. Our findings have pro-
vided new insights into the pathogenesis of breast cancer,
and indicate that TBLR1 might be a potential therapeutic
target in breast cancer.
Conclusion
We have shown that TBLR1 expression is elevated in breast
cancer cells and tissues. The elevated expression of TBLR1
is significantly correlated with the progression of breast
cancer. TBLR1 overexpression promoted, whereas TBLR1
silencing inhibited, proliferation and tumorigenicity in
breast cancer cells both in vitro and in vivo. Furthermore,
we have demonstrated that TBLR1 may promote prolifer-
ation and tumorigenicity in breast cancer cells via activa-
tion of the β-catenin signaling pathway, which provides a
novel molecular mechanism for breast cancer progres-
sion. However, further investigations are required to
elucidate the precise role of TBLR1 in the progression
of breast cancer. Our results suggest that TBLR1 may
be an effective clinical marker of disease progression
and a prognostic indicator of survival in patients with
breast cancer.
Additional files
Additional file 1: Figure S1. Expression of transducin (β)-like 1 X-linked
receptor 1 (TBLR1) is elevated in breast cancer. (A) Expression
analyses of TBLR1 mRNA in primary normal breast epithelial cells(NBECs) and cultured breast cancer cell lines by real-time PCR.
Glyceraldehyde-3-phosphate dehydrogenase was used as a loading
control. (B) Real-time PCR analysis showing expression of TBLR1
mRNA in each of the primary breast cancer tissue samples (T) and
adjacent noncancerous tissues (ANT) from the same patient. Error
bars represents the mean ± SD of three independent experiments;
*P <0.05.
Additional file 2: Figure S2. Quantitative analysis of transducin (β)-like
1 X-linked receptor 1 (TBLR1) and Ki-67 in human breast cancer
samples by immunohistochemical staining. Quantification indicates
the relationship between TBLR1 and Ki-67 expression (P <0.001);
1 = low expression; 2 = high expression.
Additional file 3: Figure S3. Transducin (β)-like 1 X-linked receptor 1
(TBLR1) increased AXIN2 expression. Real-time PCR analysis of AXIN2
expression in TBLR1-overexpressing, TBLR1-silencing, and control cells.
Glyceraldehyde-3-phosphate dehydrogenase was used as a loading
control. Error bars represents the mean ± SD of three independent
experiments; *P <0.05.
Additional file 4: Figure S4. Transducin (β)-like 1 X-linked receptor 1
(TBLR1) increased the luciferase activity of Cyclin D1 promoter. Indicated
cells transfected with Cyclin D1 promoter luciferase and Renilla pRL-TK
plasmids were subjected to dual-luciferase assays 48 hours after
transfection. Reporter activity detected was normalized by Renilla
luciferase activity. Error bars represents the mean ± SD of three
independent experiments; *P <0.05.
Additional file 5: Figure S5. Inhibition of Wnt/β-catenin signaling
blocked the functional role of transducin (β)-like 1 X-linked receptor 1
(TBLR1). (A) MTT assays showed the proliferation rate of indicated cells.
(B) Representative micrographs (left) and quantification of 5-bromodeoxy
uridine (BrdU)-positive cells. Error bars represents the mean ± SD of three
independent experiments; *P <0.05.
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